Association of Sarcoidosis and Immune Thrombocytopenia: Presentation and Outcome in a Series of 20 Patients

The association of sarcoidosis and immune thrombocytopenia (ITP) has rarely been investigated. The aim of the current retrospective study was to investigate the clinical and biological phenotypes and outcome of this association in a large series of recent patients. Twenty patients (50% men) were included. Median age at sarcoidosis and ITP diagnosis was 36 (range, 10-83 yr) and 38 (range, 21-83 yr) years, respectively. In 11 of 20 (55%) patients, sarcoidosis onset preceded ITP (median interval, 48 mo; range, 6-216 mo). In 5 of 20 (25%) patients, the 2 conditions occurred concomitantly. In 4 of 20 (20%) patients, ITP onset preceded sarcoidosis (median interval, 68 mo; range, 15-153 mo). In 4 cases, sarcoidosis and ITP were not concomitant, since 1 condition was cured before the other was declared. In 12 of 20 (60%) patients there was a simultaneous onset or relapse of both ITP and sarcoidosis. Sarcoidosis phenotype was characterized by an acute onset in 40% of patients. The visceral involvement included thoracic sites in 19 of 20 (95%) patients and extrathoracic sites in 16 of 20 (80%) patients. At ITP onset, median platelet count was 11 × 109/L (range, 3-90); 17 (85%) patients had a platelet count <30 × 109/L. Seven (35%) patients had a bleeding score >8 without visceral bleeding. Nineteen of the 20 (95%) patients were treated specifically for ITP. After the first-line therapy (prednisone at 1 mg/kg per day for at least 3 consecutive weeks in all patients; with IVIg in addition for 10 patients with severe bleeding score), 12 of 19 (63%) patients achieved a complete response, 6 (31.5%) had a partial response, and only 1 patient failed to respond. At the end of ITP follow-up (median, 70 mo; range, 12-142 mo), 18 (90%) patients achieved a complete response, 1 achieved a partial response, and 1 had no response. After a median follow-up of 105 months, 13 of 20 (65%) patients had persistent sarcoidosis requiring prolonged therapy, and thus sarcoidosis represented the main long-term concern. Main conclusions were 1) ITP presentation was usually severe, but response to treatment was favorable in almost all cases, with no death and no severe bleeding, in contrast with older reports, 2) sarcoidosis was remarkable for the high proportion of cases with an acute onset, a chronic course, and the need for prolonged prednisone therapy, 3) sarcoidosis and ITP onset and evolution were not always synchronous. Abbreviations: ALPS = autoimmune lymphoproliferative syndrome, CR = complete response to treatment, HCQ = hydroxychloroquine, ITP = immune thrombocytopenia, IVIg = intravenous immunoglobulin, NR = no response to treatment, PR = partial response to treatment.

[1]  F. Rodeghiero,et al.  Treatment practices in adults with chronic immune thrombocytopenia – a European perspective , 2010, European journal of haematology.

[2]  M. Goldacre,et al.  Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database , 2009, Postgraduate medical journal.

[3]  M. Jersild The syndrome of Heerfordt (uveo‐parotid fever), a manifestation of Boeck's sarcoid , 2009 .

[4]  A. von dem Borne,et al.  Sarcoidosis associated with autoimmune thrombocytopenia and selective IgA deficiency. , 2009, Scandinavian journal of haematology.

[5]  H. Israel,et al.  Latex fixation tests in sarcoidosis. , 2009, Acta medica Scandinavica. Supplementum.

[6]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[7]  Karina D. Torralba,et al.  Sarcoidosis and the rheumatologist , 2009, Current opinion in rheumatology.

[8]  James T.C. Li,et al.  Common variable immunodeficiency: a new look at an old disease , 2008, The Lancet.

[9]  A. Prasse,et al.  Phenotyping sarcoidosis from a pulmonary perspective. , 2008, American journal of respiratory and critical care medicine.

[10]  A. Chott,et al.  Autoimmune Lymphoproliferative Syndrome (ALPS) Caused by Fas (CD95) Mutation Mimicking Sarcoidosis , 2008, The American journal of surgical pathology.

[11]  F. Lescure,et al.  Thrombocytopenia in sarcoidosis. , 2006, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  P. Debré,et al.  The immune paradox of sarcoidosis and regulatory T cells , 2006, The Journal of experimental medicine.

[13]  D. Lauque,et al.  Les splénomégalies sarcoïdosiques : caractéristiques cliniques et évolutives. À propos de 17 observations , 2004 .

[14]  R. Gupta,et al.  Thrombocytopenia as the presenting manifestation of sarcoidosis. , 2002, The Journal of the Association of Physicians of India.

[15]  I. Gotsman,et al.  Anti-dsDNA antibodies in sarcoidosis. , 2000, Seminars in arthritis and rheumatism.

[16]  S. Varma,et al.  High-dose methyl prednisolone for autoimmune thrombocytopenia in sarcoidosis. , 1997, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[17]  C. Feighery,et al.  Anti-monocyte cytoplasmic antibodies in granulomatous disease. , 1996, Clinical immunology and immunopathology.

[18]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[19]  S. Sato,et al.  Antiphospholipid antibodies. A prognostic factor in sarcoidosis? , 1994, Chest.

[20]  C. Dollery,et al.  Life threatening thrombocytopenia in sarcoidosis. , 1990, BMJ.

[21]  S. Field,et al.  Sarcoidosis presenting as chronic thrombocytopenia. , 1987, The Western journal of medicine.

[22]  B. Coiffier,et al.  [Sarcoidosis accompanied by severe acute peripheral thrombopenia. Probable immunologic nature]. , 1982, La Nouvelle presse medicale.

[23]  W. Zinkham,et al.  Etiology and therapy of thrombocytopenia associated with sarcoidosis. , 1972, The Journal of pediatrics.

[24]  P. Bierling,et al.  Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. , 2005, Haematologica.

[25]  P. Cagle,et al.  Massive splenomegaly in sarcoidosis. , 1992, Southern medical journal.

[26]  C. Bourgain,et al.  [Sarcoidosis associated with hemolytic anemia and autoimmune thrombocytopenia]. , 1990, Annales de medecine interne.